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Abstract
We profiled nine pure clear cell carcinomas of the breast using massively parallel
DNA and RNA sequencing (NGS), in situ hybridization (ISH), and immunohistochemistry (IHC). All cases were primary mammary clear cell carcinomas that were diagnosed in female patients (mean age: 53.4 years; range: 31-69 years). Based on our
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findings, we conclude that the majority of clear cell carcinomas are ER/PR positive
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carcinomas also harbored alterations in PIK3CA/PTEN/AKT pathway, particularly

5

and consequently amenable to anti-ER treatment modalities. A subset of clear cell
PTEN, indicating a potential benefit of PI3K/Akt/mTOR inhibitors. The status of I-O
biomarkers in clear cell carcinomas indicates a limited therapeutic benefit of immune
checkpoint inhibitors (against PD-1/PD-L1).
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Clear cell differentiation may be occasionally seen in various sub-

breast using massively parallel DNA and RNA sequencing (NGS), in

types of breast cancer, but pure forms of clear cell carcinoma (>90%

situ hybridization (ISH), and immunohistochemistry (IHC). All cases

clear cell morphology) are exceptionally rare. These cancers are char-

were primary mammary clear cell carcinomas that were diagnosed in

acterized by neoplastic cells with an abundant and clear cytoplasm

female patients (mean age: 53.4 years; range: 31-69 years) (Figure 1).
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that typically contains glycogen. This type of cancer is considered

Six out of nine cases were periodic acid-Schiff (PAS) positive and

a distinct cyto-morphological pattern of invasive breast carcinoma

PAS-diastase sensitive (glycogen-rich). The NGS platform covered

of no special type (IBC-NST).1 The clinical data on clear cell carci-

exons from 592 genes (SureSelect XT, Agilent, Santa Clara, CA; and

noma are limited and predominantly include small retrospective

the NextSeq instrument, Illumina, San Diego, CA). The tumor mu-
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studies that reported the conflicting results. However, a recent

tational burden (TMB) was considered high if ≥11 mutations/mega-

Surveillance, Epidemiology, and End Results (SEER) study revealed

base were detected4 (Table 1). Microsatellite instability (MSI) was

that clear cell carcinomas tend to be pathologically high-grade can-

calculated from NGS data by direct analysis of short tandem repeat

cers that clinically present at an advanced stage and have poor out-

tracts in the target regions of sequenced genes.5 The ArcherDX
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comes. Apart from reports of variable steroid receptor (ER and PR)

FusionPlex Assay (ArcherDX, Boulder, CO) was used for gene fu-

and HER2 positivity, no studies have systematically explored molec-

sion assessment (n = 54; Table 1). The following biomarkers were

ular features and potentially targetable biomarkers in clear cell car-

tested by immunohistochemistry (IHC): steroid receptors (ER, PR,

cinomas. 2 Herein, we profiled nine pure clear cell carcinomas of the

AR, ARv7), HER2, pTRK, PD-L1, PTEN, and mismatch repair proteins
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(MLH1, MSH2, MSH6, and PMS2) (clones and thresholds for posi-

ER is uncertain. Alterations within the PI3K/Akt/mTOR pathway

Both ER and PR were positive in

are among the most common genomic alterations in breast cancer.8

the majority of cases (8+/9 cases each) (Table 1). AR was positive in

A subset of clear cell carcinomas also harbored alterations in this

7/9 cases (78%) without the presence of the ARv7 splice variant. No

pathway, particularly PTEN, indicating a potential benefit of PI3K/

case was HER2 positive by IHC or ISH (0%). Pathogenic mutations

Akt/mTOR inhibitors. A complete loss of PTEN protein expression

tivity are provided in Table S1).

4,6,7

were detected in three cases: PIK3R1 and BRCA2 (#1); TP53, PTEN,

without detected PTEN gene mutations in two cases indicates an al-

and CDKN2A (#2); and TP53 and BCOR1 genes (#3) (Table 1). PTEN

ternative silencing mechanism of this important tumor suppressor.

protein loss was confirmed by IHC in the one PTEN-mutated case as

The observed alterations in clear cell carcinomas may be clinically

well as in two additional cases without detectable PTEN gene muta-

relevant given that the Food and Drug Administration (FDA) has re-

tions (Table 1). No gene fusion was detected in any of the cases. Low

cently approved a PIK3CA inhibitor Piqray (alpelisib) combined with

PD-L1 expression (1%-10%) was exclusively seen in immune cells in

fulvestrant for the treatment of ER+/PIK3CA-mutated metastatic

3/8 cases (Figure 1); notably, one of the PD-L1 + cases had an under-

breast carcinomas. In addition, two of three clear cell carcinomas

lying PTEN gene mutation (Table 2, Figure 1). All tested cases (n = 8)

with PI3K/PTEN alterations were AR+. A recent clinical trial showed

were MSI stable (by NGS or IHC) and had low TMB (3-7 mutations/

the therapeutic benefit of combined anti-AR (enzalutamide) and

megabase) (n = 4) (Table 2).

PIK3CA inhibitor (taselisib) in TNBC patients whose cancers were

Based on our findings, we conclude that the majority of clear

AR+.9 Interestingly, one of the clear cell cases harbored a CDKN2A

cell carcinomas are ER/PR positive and consequently amenable to

(P16INK4A) gene mutation; several studies have revealed mutations

anti-ER treatment modalities. Although not routinely assessed, the

in this gene in a proportion of breast carcinomas [reviewed in10].

importance of AR expression in breast cancer has been increasingly

The discovery of genetic alterations of CDKN2A as well as other cell

recognized,1 particularly in triple-negative breast cancer (TNBC).

cycle regulators in breast cancers has led to the approval of CDK4/6

Although we found frequent AR overexpression in clear cell carci-

inhibitors (palbociclib) for the treatment of ER+/HER2- advanced/

nomas without the ARv7 splice variant, potential therapeutic benefit

metastatic breast carcinomas.10,11 In recent years, immunother-

of anti-AR–based therapy alone in clear cell carcinomas expressing

apy based on immune checkpoint inhibitors (against PD-1/PD-L1)

F I G U R E 1 Case #4: a tumor with clear
cell morphology (left image, 20x) with PDL1 expression (~10%) detected exclusively
in immune cells (right image) (PD-L1,
SP142 clone, Ventana, 20x)

TA B L E 1

Overview of the potentially targetable biomarkers in cell carcinomas of the breast

Case

ER and PR

AR and ARv7

HER2 status

Mutational profile

Gene fusions
(NTRK)b

#1

ER (+), PR (+)

AR (+)

Negative

None

None

#2

ER (+), PR (+)

AR (−)

Negative

n/a

None

#3

ER (+), PR (−)

AR (+), ARv7 (−)

Negative

None

None
a

None

#4

ER (+), PR (+)

AR (+), ARv7 (−)

Negative

BRCA2, PIK3R1, PTEN loss

#5

ER (+), PR (+)

AR (+), ARv7 (−)

Negative

n/a

None

#6

ER (+), PR (+)

AR (+), ARv7 (−)

Negative

PTEN, TP53, CDKN2A

None

#7

ER (+), PR (+)

AR (+), ARv7 (−)

Negative

n/a

None

#8

ER (+), PR (+)

AR (+), ARv7 (−)

Negative

n/a

None

#9

ER (−), PR (+)

AR (−)

Negative

TP53, BCOR, PTEN lossa

None

Abbreviations: AR, androgen receptor; ARv7, androgen receptor splice variant 7; ER, estrogen receptor; HER2, human epidermal growth factor
receptor 2; NTRK, neurotrophic receptor tyrosine kinase; PR, progesterone receptor.
a

PTEN loss was observed by immunohistochemistry. Case #6 with PTEN gene mutation also exhibited PTEN protein loss by IHC.

b

ArcherDX FusionPlex Assay (ArcherDX, Boulder, CO) was used to assess gene fusions (n = 54) (the panel is available here: https://www.carismolec
ularintelligence.com/wp-content/uploads/2017/03/TN0276-v14_Profile-Menu.pdf). NTRK status was also assessed by immunohistochemistry.¸
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TA B L E 2 The status of immuno-oncology (I-O) biomarkers in
clear cell carcinomas of the breast
I-O biomarkers

Status in clear cell carcinomas

PD-L1 expression (n = 8)

3/8 positive in immune cells (1%10% positivity) No expression in
cancer cells

Tumor mutational burden
(TMB)a (n = 4)

4/4 low (5-7 mutations/
megabase)

Microsatellite instability (MSI)
(n = 8)

8/8 MSI stable

Abbreviations: I-O, immuno-oncology.
a

TMB was considered high if ≥11 mutations/megabase were detected.
The estimated threshold was based on a cohort of 603 triple-negative
breast carcinomas of no special type using an 80th percentile cutoff
value.14

has dramatically improved the treatment options and outcomes of
several cancers including TNBC. The selection of patients for these
drugs is based on several predictive biomarkers (I-O biomarkers) including PD-L1 expression (on cancer or immune cells) and TMB and
MSI status. The status of I-O biomarkers in clear cell carcinomas indicates a limited therapeutic benefit of immune checkpoint inhibitors
(against PD-1/PD-L1). The presence of a PTEN mutation in one of the
PD-L1+ cases may suggest resistance to immune checkpoint inhibitors.12,13 Nevertheless, finding immune cell PD-L1 expression in a
subset of clear cell carcinomas warrants further investigations given
the approved treatment for TNBC with atezolizumab is solely based
on immune cell expression of PD-L1 (source: FDA, https://www.fda.
gov/drugs/drug-approvals-and-databases/fda-approves-atezolizum
ab-pd-l1-positive-unresectable-locally-advanced-or-metast atic-tripl
e-negative, accessed on March 2, 2020). MSI and TMB status in clear
cell carcinomas of the breast is similar to that in IBC-NST.14,15
In conclusion, clear cell carcinomas of the breast have limited
targeted therapy options, but comprehensive molecular profiling
may guide single or combined targeted treatments in selected
cases.
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The preliminary data from the current study were presented at the
USCAP 109th Annual Meeting, February 2020, Los Angeles, CA, USA.
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